What is Nuclera?
Nuclera is at the forefront of democratizing biology through its innovative eProtein desktop bioprinting technology. Founded in 2013 by a group of PhD students from the University of Cambridge who sought to overcome the inherent inaccessibility of biological research tools, the company aims to empower scientists and researchers. By providing streamlined access to next-day protein supplies via desktop bioprinting, Nuclera enables a more agile and controlled approach to biological experimentation, fostering innovation and accelerating discovery within the life sciences.
How much funding has Nuclera raised?
Nuclera has raised a total of $157.6M across 5 funding rounds:
Series A
$11.2M
Series B
$58M
Grant
$1.4M
Series C
$75M
Series C
$12M
Series A (2018): $11.2M with participation from RT Partners
Series B (2022): $58M led by RT Partners, Future Planet Capital, M&G, Amadeus Capital Partners, Jonathan Milner, E Ink, and Verve Ventures
Grant (2024): $1.4M supported by UK Research & Innovation
Series C (2024): $75M featuring British Patient Capital, Cambridge Innovation Capital, Patient Square Capital, and Elevage Medical Technologies
Series C (2026): $12M backed by G K Goh Holdings, British Business Bank, and Elevage Medical Technologies
Key Investors in Nuclera
British Patient Capital
British Patient Capital, part of the government-owned British Business Bank, specializes in providing financial support and equity finance to growing UK businesses, with a focus on innovative companies.
Cambridge Innovation Capital
Cambridge Innovation Capital is a venture investor focused on life sciences and deep tech within the Cambridge ecosystem, leveraging its ties with the University of Cambridge to back innovative start-ups.
Patient Square Capital
Patient Square Capital is a specialized investment firm with a dedicated focus on the healthcare industry, aiming to support companies that improve patient outcomes and advance medical innovation.
What's next for Nuclera?
The substantial enterprise-level capital infusion, including the recent strategic investment, positions Nuclera for accelerated scaling and further technological development. This backing is expected to fuel advancements in their eProtein technology, expand market reach, and solidify their position as a leader in accessible bioprinting solutions. The company's focus on empowering researchers suggests a strategy geared towards broad adoption and integration into standard laboratory workflows, potentially leading to significant breakthroughs in biological research and development.
See full Nuclera company page
